Detailed information for compound 214467

Basic information

Technical information
  • TDR Targets ID: 214467
  • Name: tert-butyl N-[2-[4-[[1-(5-benzamido-2-bromoph enyl)-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl ]-3-fluorophenyl]phenyl]sulfonylcarbamate
  • MW: 750.634 | Formula: C35H33BrFN5O6S
  • H donors: 2 H acceptors: 5 LogP: 6.47 Rotable bonds: 13
    Rule of 5 violations (Lipinski): 2
  • SMILES: CCc1nn(c(=O)n1Cc1ccc(cc1F)c1ccccc1S(=O)(=O)NC(=O)OC(C)(C)C)c1cc(ccc1Br)NC(=O)c1ccccc1
  • InChi: 1S/C35H33BrFN5O6S/c1-5-31-39-42(29-20-25(17-18-27(29)36)38-32(43)22-11-7-6-8-12-22)34(45)41(31)21-24-16-15-23(19-28(24)37)26-13-9-10-14-30(26)49(46,47)40-33(44)48-35(2,3)4/h6-20H,5,21H2,1-4H3,(H,38,43)(H,40,44)
  • InChiKey: PLKVKLNGSGPVQK-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • tert-butyl N-[2-[4-[[1-(5-benzamido-2-bromo-phenyl)-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluoro-phenyl]phenyl]sulfonylcarbamate
  • N-[2-[4-[[1-(5-benzamido-2-bromophenyl)-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamic acid tert-butyl ester
  • N-[2-[4-[[1-(5-benzamido-2-bromo-phenyl)-3-ethyl-5-keto-1,2,4-triazol-4-yl]methyl]-3-fluoro-phenyl]phenyl]sulfonylcarbamic acid tert-butyl ester
  • tert-butyl N-[2-[4-[[1-[5-(benzoylamino)-2-bromophenyl]-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate
  • tert-butyl N-[2-[4-[[1-[5-(benzoylamino)-2-bromo-phenyl]-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluoro-phenyl]phenyl]sulfonylcarbamate
  • N-[2-[4-[[1-[2-bromo-5-[(oxo-phenylmethyl)amino]phenyl]-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamic acid tert-butyl ester
  • N-[2-[4-[[1-[5-(benzoylamino)-2-bromo-phenyl]-3-ethyl-5-keto-1,2,4-triazol-4-yl]methyl]-3-fluoro-phenyl]phenyl]sulfonylcarbamic acid tert-butyl ester
  • tert-butyl N-[2-[4-[[1-[2-bromo-5-(phenylcarbonylamino)phenyl]-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluoro-phenyl]phenyl]sulfonylcarbamate

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Angiotensin II type 2 (AT-2) receptor Starlite/ChEMBL References
Oryctolagus cuniculus Angiotensin II type 1a (AT-1a) receptor Starlite/ChEMBL References
Rattus norvegicus Angiotensin II receptor (AT-1) type-1 Starlite/ChEMBL References
Homo sapiens angiotensin II receptor, type 2 Starlite/ChEMBL References
Homo sapiens angiotensin II receptor, type 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma mansoni peptide (FMRFamide/somatostatin)-like receptor Angiotensin II type 1a (AT-1a) receptor   359 aa 346 aa 18.2 %
Echinococcus multilocularis neuropeptide receptor Angiotensin II type 2 (AT-2) receptor   363 aa 308 aa 21.4 %
Onchocerca volvulus Angiotensin II type 1a (AT-1a) receptor   359 aa 313 aa 25.6 %
Loa Loa (eye worm) neuropeptide F receptor Angiotensin II type 2 (AT-2) receptor   363 aa 356 aa 23.3 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor angiotensin II receptor, type 1 359 aa 403 aa 19.1 %
Onchocerca volvulus Angiotensin II type 1a (AT-1a) receptor   359 aa 296 aa 23.0 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor Angiotensin II type 2 (AT-2) receptor   363 aa 398 aa 18.3 %
Onchocerca volvulus Angiotensin II type 1a (AT-1a) receptor   359 aa 341 aa 23.2 %
Brugia malayi ORL1-like opioid receptor Angiotensin II type 1a (AT-1a) receptor   359 aa 333 aa 21.3 %
Brugia malayi GnHR receptor homolog Angiotensin II type 1a (AT-1a) receptor   359 aa 364 aa 20.3 %
Echinococcus multilocularis G-protein coupled receptor, putative Angiotensin II type 1a (AT-1a) receptor   359 aa 307 aa 22.5 %
Onchocerca volvulus Angiotensin II type 2 (AT-2) receptor   363 aa 306 aa 22.5 %
Schistosoma mansoni adenoreceptor Angiotensin II type 2 (AT-2) receptor   363 aa 328 aa 22.0 %
Schistosoma japonicum Rhodopsin, putative Angiotensin II type 2 (AT-2) receptor   363 aa 341 aa 22.0 %
Echinococcus multilocularis pyroglutamylated rfamide peptide receptor Angiotensin II type 2 (AT-2) receptor   363 aa 398 aa 18.1 %
Loa Loa (eye worm) hypothetical protein Angiotensin II type 1a (AT-1a) receptor   359 aa 308 aa 27.3 %
Schistosoma mansoni peptide (allatostatin)-like receptor Angiotensin II type 2 (AT-2) receptor   363 aa 364 aa 20.9 %
Schistosoma mansoni opsin-like receptor Angiotensin II type 1a (AT-1a) receptor   359 aa 299 aa 25.1 %
Echinococcus multilocularis tm gpcr rhodopsin gpcr rhodopsin superfamily Angiotensin II type 1a (AT-1a) receptor   359 aa 306 aa 21.9 %
Onchocerca volvulus Angiotensin II receptor (AT-1) type-1   359 aa 309 aa 18.8 %
Echinococcus granulosus allatostatin A receptor Angiotensin II type 2 (AT-2) receptor   363 aa 340 aa 24.1 %
Echinococcus multilocularis allatostatin A receptor Angiotensin II type 2 (AT-2) receptor   363 aa 342 aa 24.6 %
Echinococcus granulosus growth hormone secretagogue receptor type 1 Angiotensin II type 1a (AT-1a) receptor   359 aa 342 aa 22.2 %
Brugia malayi putative neuropeptide receptor NPR1 Angiotensin II type 1a (AT-1a) receptor   359 aa 295 aa 27.1 %
Echinococcus granulosus tm gpcr rhodopsin Angiotensin II type 1a (AT-1a) receptor   359 aa 306 aa 21.9 %
Onchocerca volvulus Angiotensin II type 1a (AT-1a) receptor   359 aa 399 aa 25.3 %
Loa Loa (eye worm) hypothetical protein Angiotensin II type 1a (AT-1a) receptor   359 aa 335 aa 23.0 %
Schistosoma japonicum ko:K04209 neuropeptide Y receptor, invertebrate, putative Angiotensin II type 2 (AT-2) receptor   363 aa 310 aa 23.5 %
Schistosoma mansoni biogenic amine (octopamine/dopamine) receptor Angiotensin II type 1a (AT-1a) receptor   359 aa 364 aa 23.1 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor angiotensin II receptor, type 2 363 aa 398 aa 18.3 %
Onchocerca volvulus Angiotensin II type 2 (AT-2) receptor   363 aa 305 aa 21.6 %
Onchocerca volvulus Angiotensin II type 2 (AT-2) receptor   363 aa 311 aa 23.8 %
Onchocerca volvulus E3 ubiquitin-protein ligase rpm-1 homolog Angiotensin II type 1a (AT-1a) receptor   359 aa 328 aa 20.7 %
Schistosoma japonicum ko:K04134 cholinergic receptor, invertebrate, putative Angiotensin II type 1a (AT-1a) receptor   359 aa 325 aa 20.9 %
Echinococcus granulosus neuropeptide receptor Angiotensin II type 2 (AT-2) receptor   363 aa 306 aa 22.2 %
Echinococcus granulosus thyrotropin releasing hormone receptor Angiotensin II type 2 (AT-2) receptor   363 aa 308 aa 22.1 %
Echinococcus multilocularis thyrotropin releasing hormone receptor Angiotensin II type 2 (AT-2) receptor   363 aa 308 aa 21.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Toxoplasma gondii polyprenyl synthetase superfamily protein 0.4495 1 1
Brugia malayi Calcitonin receptor-like protein seb-1 0.1298 0.1139 0.1139
Brugia malayi geranylgeranyl pyrophosphate synthetase 0.1611 0.2005 0.2005
Echinococcus multilocularis geranylgeranyl pyrophosphate synthase 0.1611 0.2005 0.0646
Echinococcus granulosus farnesyl pyrophosphate synthase 0.4495 1 1
Trypanosoma cruzi farnesyl pyrophosphate synthase, putative 0.4495 1 1
Chlamydia trachomatis geranylgeranyl pyrophosphate synthase 0.1412 0.1453 0.5
Echinococcus multilocularis decaprenyl diphosphate synthase subunit 1 0.2036 0.3184 0.2025
Trypanosoma cruzi solanesyl-diphosphate synthase, putative 0.2036 0.3184 0.1474
Trypanosoma cruzi solanesyl-diphosphate synthase, putative 0.2036 0.3184 0.1474
Trypanosoma cruzi solanesyl-diphosphate synthase 0.2036 0.3184 0.1474
Schistosoma mansoni trans-prenyltransferase 0.2036 0.3184 0.3184
Loa Loa (eye worm) polyprenyl synthetase 0.2036 0.3184 0.3184
Schistosoma mansoni glutathione synthetase 0.1412 0.1453 0.1453
Loa Loa (eye worm) hypothetical protein 0.1298 0.1139 0.1139
Trypanosoma brucei farnesyl pyrophosphate synthase 0.4495 1 1
Plasmodium falciparum geranylgeranyl pyrophosphate synthase, putative 0.4495 1 1
Treponema pallidum octaprenyl-diphosphate synthase 0.1611 0.2005 0.5
Echinococcus multilocularis farnesyl pyrophosphate synthase 0.4495 1 1
Echinococcus granulosus geranylgeranyl pyrophosphate synthase 0.1611 0.2005 0.0646
Entamoeba histolytica geranylgeranyl pyrophosphate synthetase, putative 0.2036 0.3184 1
Giardia lamblia Farnesyl diphosphate synthase 0.4495 1 0.5
Loa Loa (eye worm) polyprenyl synthetase 0.4495 1 1
Schistosoma mansoni geranylgeranyl pyrophosphate synthase 0.1611 0.2005 0.2005
Mycobacterium ulcerans polyprenyl diphosphate synthetase, GrcC1 0.2036 0.3184 0.2025
Loa Loa (eye worm) pigment dispersing factor receptor c 0.1298 0.1139 0.1139
Entamoeba histolytica geranylgeranyl pyrophosphate synthase, putative 0.2036 0.3184 1
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.4495 1 0.5
Leishmania major solanesyl-diphosphate synthase, putative 0.2036 0.3184 0.1474
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.4495 1 1
Mycobacterium leprae PROBABLE POLYPRENYL-DIPHOSPHATE SYNTHASE GRCC1 (POLYPRENYL PYROPHOSPHATE SYNTHETASE) 0.2036 0.3184 0.5
Brugia malayi Corticotropin releasing factor receptor 2 precursor, putative 0.1298 0.1139 0.1139
Echinococcus granulosus decaprenyl diphosphate synthase subunit 1 0.2036 0.3184 0.2025
Plasmodium vivax geranylgeranyl pyrophosphate synthase 0.4495 1 1
Trypanosoma cruzi farnesyl pyrophosphate synthase 0.4495 1 1
Schistosoma mansoni farnesyl pyrophosphate synthase 0.4495 1 1
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.4495 1 0.5
Mycobacterium tuberculosis Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) 0.4495 1 1
Loa Loa (eye worm) geranylgeranyl pyrophosphate synthetase 0.1611 0.2005 0.2005
Trichomonas vaginalis geranylgeranyl diphosphate synthase, putative 0.4495 1 0.5
Brugia malayi Polyprenyl synthetase family protein 0.2036 0.3184 0.3184
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.4495 1 1
Leishmania major farnesyl pyrophosphate synthase 0.4495 1 1
Wolbachia endosymbiont of Brugia malayi geranylgeranyl pyrophosphate synthase 0.2036 0.3184 1

Activities

Activity type Activity value Assay description Source Reference
Duration (functional) 0 hr Duration of action (inhibtion of AII pressor response) following peroral administration at dose 3.0 mg/kg; not determined; Duration ranges from <1 to 6 h ChEMBL. 7562905
Duration (functional) > 6 hr Duration of action (inhibtion of AII pressor response) following intravenous administration at dose 3.0 mg/kg; >6<24 ChEMBL. 7562905
Duration (functional) > 6 hr Duration of action (inhibtion of AII pressor response) following peroral administration at dose 10.0 mg/kg; >6<24 ChEMBL. 7562905
IC50 (binding) = 8.823 Antagonist activity at Oryctolagus cuniculus (rabbit) aortic AT1 receptor ChEMBL. No reference
IC50 (binding) = 0.18 nM In vitro inhibitory activity against angiotensin II type 2 receptor in rat adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 0.18 nM In vitro inhibitory activity against angiotensin II type 2 receptor in rat adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 0.48 nM In vitro inhibitory activity against angiotensin II type 1 receptor in rat adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 0.48 nM In vitro inhibitory activity against angiotensin II type 1 receptor in rat adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 0.93 nM In vitro inhibitory activity against Angiotensin II receptor, type 2 in rat midbrain membrane preparations. ChEMBL. 7562905
IC50 (binding) = 0.93 nM In vitro inhibitory activity against Angiotensin II receptor, type 2 in rat midbrain membrane preparations. ChEMBL. 7562905
IC50 (binding) = 1.5 nM In vitro inhibitory activity against Angiotensin II receptor, type 1 in rabbit aorta membrane preparations. ChEMBL. 7562905
IC50 (binding) = 1.5 nM In vitro inhibitory activity against Angiotensin II receptor, type 1 in rabbit aorta membrane preparations. ChEMBL. 7562905
IC50 (binding) = 1.5 nM Antagonist activity at Oryctolagus cuniculus (rabbit) aortic AT1 receptor ChEMBL. No reference
IC50 (binding) = 4.1 nM In vitro inhibitory activity against Angiotensin II receptor type 2 in human adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 4.1 nM In vitro inhibitory activity against Angiotensin II receptor type 2 in human adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 24 nM In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations. ChEMBL. 7562905
IC50 (binding) = 24 nM In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations. ChEMBL. 7562905
Inhibition (functional) = 55 % In vivo inhibtion of AII pressor response was measured in conscious, normotensive rats after peroral administration at dose 3.0 mg/kg ChEMBL. 7562905
Inhibition (functional) = 100 % In vivo inhibtion of AII pressor response was measured in conscious, normotensive rats after intravenous administration at dose 3.0 mg/kg ChEMBL. 7562905
Inhibition (functional) = 100 % In vivo inhibtion of AII pressor response was measured in conscious, normotensive rats after peroral administration at dose 10.0 mg/kg ChEMBL. 7562905
Ratio (binding) = 0.2 IC50 ratio of human adrenal AT2 receptor to AT1 receptor. ChEMBL. 7562905
Ratio (binding) = 0.4 IC50 ratio 0f AT2 to AT1 receptor (rat adrenal) ChEMBL. 7562905
Ratio (binding) = 0.6 IC50 ratio of AT2 receptor from rabbit aorta to AT1 receptor from rat midbrain. ChEMBL. 7562905
Ratio (binding) = 0.2 IC50 ratio of human adrenal AT2 receptor to AT1 receptor. ChEMBL. 7562905
Ratio (binding) = 0.4 IC50 ratio 0f AT2 to AT1 receptor (rat adrenal) ChEMBL. 7562905
Ratio (binding) = 0.6 IC50 ratio of AT2 receptor from rabbit aorta to AT1 receptor from rat midbrain. ChEMBL. 7562905

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.